MAM
ESS ups Sanjay Kailash to head of sales
MUMBAI: ESPN Star Sports (ESS) has promoted Sanjay Kailash to ESPN Software India (ESI) executive VP and head of sales.
He will have an expanded role with the overall responsibility of delivering revenue for various streams of the business including advertising, affiliate sales, digital media and event management group. He will continue to report directly to ESI MD Aloke Malik.
Malik said, “As we further scale up our business in the market with new networks and offerings, we see great potential in bringing more synergy across different revenue functions. This will allow us to explore more opportunities and develop focused propositions for our business partners. Sanjay’s in-depth knowledge and cross-industry experience will help ESPN Software India further reinforce and broaden its business in the sub-continent, and I believe the organization will benefit from his contributions through this new role.”
Kailash has been with the company for over 10 years, having made significant and consistent contributions to the ad sales function. Most recently, he led the ICC Cricket World Cup ad sales effort. In addition, he has been keenly involved in the programming and scheduling aspects of the business and contributed to the start-up of the event management group in India, as well as growing the Digital Media business for the company, the company said.
TS Panesar will continue to head Affiliate Sales including both Cable & DTH business and ad sales will be led by Anup Govindan, both of whom will report to Kailash.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
